Parkinson’s disease (PD), also known as Parkinsonism, is a neurological condition that mostly, but not solely, impairs movement control. It is distinguished by an increased deterioration and loss of dopamine-producing neurons in the substantia nigra area of the brain. The exact aetiology of PD is complicated and multifaceted. It is considered to comprise a blend of genetic vulnerability and environmental variables that contribute to the development of the condition. Some of the important reasons include heredity, the pile-up of abnormal alpha-synuclein proteins in the brain and enteric nervous systems, heavy metal neurotoxicity, head trauma, and so on. Over the years, the diagnosis of PD has mostly hinged on the clinical triad of its movement-related symptoms: tremor, rigidity, and bradycardia. Though these symptoms are not prodromal of PD, they are often detected in the extremely severe phase of the illness when therapies and treatments are no longer highly effective. Therefore, this review focuses on the need for understanding the prodromal biomarkers associated with PD, such as non-motor biomarkers, biochemical biomarkers, and inflammatory biomarkers, as well as advances in neuroimaging biomarkers, in order to facilitate new diagnostic methods other than the normal motor symptoms to aid early diagnosis and responsive therapies and treatments of the disease. Some new discoveries, such as that of distinct neural networks and pathways of the illness, combination biomarkers, and salivary gland biopsy, are promising and could assist to quickly detect the condition. <!----> <!----> <!----> <!---->